Recent studies have centered on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GIP agonists are widely employed for managing type 2 diabetes, their emerging effects on reinforcement circuits, specif